Tokyo, July 6, 2006 (JCN) - Bristol-Myers has filed an application for an additional indication of Briplatin Injection, its proprietary anti-tumor agent, with the Ministry of Health, Labor and Welfare. The company is currently seeking approval for a combination therapy of Briplatin (cisplatin) and pemetrexed for malignant pleural mesothelioma, a malignant tumor induced by exposure to asbestos.
